Nevertheless, both genes follow cancer-specific patterns of amplification, with Atox1 and CCS being amplified at a maximal level in kidney renal-cell carcinoma (KIRC) (23.1%) and breast cancer (BRCA) (18.1%) diseases, respectively (Fig. 9C). This evidence concerns the gene ATOX1 and breast cancer.